Amrubicin (AMR) Trial in Patients With Non-small Cell Lung Cancer

• Status: Completed
• Trial end date: 2014-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The study is to evaluate the effect of amrubicin (AMR) compared to docetaxel (DOC) in the treatment of non-small cell lung cancer (NSCLC).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sumitomo Dainippon Pharma Co., Ltd.
• Treatments: Amrubicin; Docetaxel

Criteria

Inclusion Criteria:

• Histological or cytological diagnosis of non-small cell lung cancer (NSCLC)

• 1 or 2 prior chemotherapy regimen including 1 platinum-based chemotherapy

• 20 or older but younger than 75 years of age

Exclusion Criteria:

• Symptomatic brain metastasis

• Interstitial pneumonia or pulmonary fibrosis

• Abnormal cardiac function or myocardial infraction within 6 months before study enrollment

• Active infection